We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
Cap. Flow
+$518M
Cap. Flow %
0.87%
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$68M
2
TFC icon
Truist Financial
TFC
+$55.9M
3
NOW icon
ServiceNow
NOW
+$33.3M
4
UBER icon
Uber
UBER
+$21.4M
5
LVS icon
Las Vegas Sands
LVS
+$15.7M

Sector Composition

Rank Sector Weight
1 Technology 19.57%
2 Financials 15.53%
3 Healthcare 13.38%
4 Consumer Discretionary 10.07%
5 Industrials 9.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SAMG icon
2826
Silvercrest Asset Management
SAMG
$79.9M
$143K ﹤0.01%
11,363
+349
+3% +$4.4K
CRMD icon
2827
CorMedix
CRMD
$590M
$142K ﹤0.01%
19,462
+132
+0.7% +$807
AFI
2828
DELISTED
Armstrong Flooring, Inc.
AFI
$142K ﹤0.01%
33,362
-592
-2% -$2.9K
VIA
2829
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
$141K ﹤0.01%
3,049
+25
+0.8% +$1.25K
ADMS
2830
DELISTED
Adamas Pharmaceuticals
ADMS
$141K ﹤0.01%
37,320
+154
+0.4% +$737
MLP icon
2831
Maui Land & Pineapple Co
MLP
$352M
$140K ﹤0.01%
12,480
+50
+0.4% +$533
NGVC icon
2832
Vitamin Cottage Natural Grocers
NGVC
$750M
$136K ﹤0.01%
13,763
+64
+0.5% +$588
TYME
2833
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$136K ﹤0.01%
96,861
-888
-0.9% -$1.08K
YELL
2834
DELISTED
Yellow Corporation Common Stock
YELL
$136K ﹤0.01%
53,364
-1,336
-2% -$4.58K
SB icon
2835
Safe Bulkers
SB
$789M
$135K ﹤0.01%
79,508
-584
-0.7% -$1.01K
NBEV
2836
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$135K ﹤0.01%
74,391
+1,038
+1% +$2.46K
ASRT
2837
DELISTED
Assertio
ASRT
$134K ﹤0.01%
1,792
-2,226
-55% -$130K
III icon
2838
Information Services Group
III
$210M
$134K ﹤0.01%
53,131
-260
-0.5% -$617
LITS
2839
Lite Strategy Inc
LITS
$32.1M
$133K ﹤0.01%
2,680
+100
+4% +$3.72K
PRGX
2840
DELISTED
PRGX Global, Inc.
PRGX
$133K ﹤0.01%
27,012
-172
-0.6% -$834
DLTH icon
2841
Duluth Holdings
DLTH
$159M
$132K ﹤0.01%
12,501
+111
+0.9% +$1.03K
NVAX icon
2842
Novavax
NVAX
$1.26B
$132K ﹤0.01%
33,098
-330
-1% -$1.43K
LCUT icon
2843
Lifetime Brands
LCUT
$197M
$130K ﹤0.01%
18,638
-132
-0.7% -$949
SAN icon
2844
Banco Santander
SAN
$207B
$130K ﹤0.01%
32,831
-549
-2% -$2.13K
ZYNE
2845
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$130K ﹤0.01%
21,505
+624
+3% +$4.27K
IMXI icon
2846
International Money Express
IMXI
$370M
$128K ﹤0.01%
+10,653
New +$145K
ELVT
2847
DELISTED
Elevate Credit, Inc.
ELVT
$127K ﹤0.01%
28,465
-212
-0.7% -$885
CHMA
2848
DELISTED
Chiasma, Inc. Common Stock
CHMA
$127K ﹤0.01%
25,682
+3,464
+16% +$18K
FLNT
2849
Fluent
FLNT
$104M
$124K ﹤0.01%
8,256
+91
+1% +$1.23K
NOVA
2850
DELISTED
Sunnova Energy
NOVA
$124K ﹤0.01%
11,131
+880
+9% +$9.17K

Similar funds

RhumbLine Advisers's Q4 2019 Portfolio in Review

As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
  • RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
  • RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
  • RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
  • RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
  • RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
  • RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.

Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.